🚀 Exciting News! 🚀 We are delighted to share that Navigo Proteins GmbH will be attending the PEGS Boston 2024! Both of our business units will be represented at the event. As pioneers in the field of protein purification, we are eager to showcase our cutting-edge Next-Gen Affinity Chromatography technology. Additionally, we'll spotlight our other business unit's innovative solutions of advancing Affilin®-based therapeutics in biotechnology. Join us at PEGS Boston 2024 to explore how our expertise and diverse capabilities can accelerate your research and development efforts. Let's connect, collaborate, and shape the future of biotechnology together! #NavigoProteins #PEGSBoston #protein #innovation #NextGen #biotech
Navigo Proteins GmbH
Biotechnology Research
Unique Affinity Solutions for Biopharmaceutical Manufacturing and Biotherapeutics
About us
Navigo Proteins discovers and develops novel scaffold proteins-based affinity ligands for commercial biologics GMP purification or as biopharmaceutical drugs/binders. They are all small, stable, highly engineerable, selective, and economically, homogeneously producible. In PRECISION CAPTURING a protein A-like scaffold serves for an antibody-like capture step even of non-Fc bearing molecules. In PRECISION TARGETING human ubiquitin is the basis for highly selective Affilin® ligands as part of a broad range of biopharmaceutical drugs. Navigo Proteins’ unique protein engineering expertise is the basis a world-wide unique, versatile scaffold proteins platform. Our robust, rapid and reliable high-throughput-based, robotics assisted platform designs, produces, analyzes and selects suitable affinity ligand proteins, optimized for their tasks in industrial downstream processing or as biopharmaceutical drugs. PRECISION CAPTURING creates custom ligands against any biologic, Fc-independent, and enables antibody-like affinity downstream processes, with competitive binding capacities, caustic stabilities, usage-cycles, flow rates and commercially available off-the-shelf leaching assays. It is applicable for purifying any recombinant protein, mAb, virus, VLP, cell, etc. Navigo Proteins has established partnerships worldwide to convert its custom affinity ligands into ready-to-use, GMP-compliant affinity resins for commercial downstream processing. Our PRECISION TARGETING platform creates tailored ligands which bind any desired biologic in biopharmaceutical or in diagnostic use, e.g. radiopharmaceuticals, Protein-drug-conjugates, CAR-T ligands or theranostics, in which the same Affilin® binder is employed in diagnosis, treatment and treatment-monitoring. Navigo Proteins is about 50 heads strong, steadily growing and based in Halle, S/W of Berlin. We offer our expertise to interested pharma, biotech and life sciences companies. https://www.navigo-proteins.com/imprint
- Website
-
http://www.navigo-proteins.com
External link for Navigo Proteins GmbH
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Halle/Saale
- Type
- Privately Held
- Founded
- 2017
- Specialties
- Protein Engineering, Affinity Chromatography, Downstream Processing, Protein-Drug-Conjugates, target specific delivery, and Radiopharmaceuticals
Locations
-
Primary
Get directions
Heinrich-Damerow-Str. 1
Halle/Saale, 06120, DE
Employees at Navigo Proteins GmbH
-
Andreas Richter
Chief Financial Officer at Navigo Proteins GmbH
-
Clemens Moritz
Senior Manager Controlling & Accounting
-
Ulrich Haupts
Chief Scientific Officer & Managing Director bei Navigo Proteins GmbH
-
Michael N.
Teamleiter bei Navigo Proteins GmbH | Proteinanalytik & Downstreamentwicklung, Dr. in Biochemie
Updates
-
Join us at BioProcess International Europe in Vienna to discover how Navigo Proteins GmbH is shaping the future with next-gen Affinity Chromatography solutions. We look forward to meeting you and discussing how we can collaborate to drive innovation and efficiency in the biopharmaceutical industry. See you in Vienna! #downstream #biotech #pharma #affinitychromatography #purification
-
-
Wir freuen uns, in diesem Jahr die "Jugend forscht"-Initiative in Sachsen-Anhalt unterstützen zu können. Für die kommende Woche wünschen wir dem MINT-Nachwuchs eine erfolgreiche Präsentation ihrer Projekte und allen Teilnehmenden eine inspirierende Veranstaltung. #jugendforscht #wissenschaft #mint
𝗘𝗜𝗡𝗙𝗔𝗖𝗛 𝗗𝗔𝗡𝗞𝗘! ❤️ Jugend forscht und Schüler experimentieren steht in diesem Jahr unter dem Motto "Mach dir einen Kopf". 🧠 Scheinbar ein Aufruf, auf den die Jungforschenden gewartet haben, denn in diesem Jahr gibt es mehr Anmeldungen und wieder einmal beeindruckende Projekte. Die besten Arbeiten aus #SachsenAnhalt werden am 🔜 4. und 5. April beim Landeswettbewerb präsentiert. Damit dieser erneut am Technologiepark Weinberg Campus in hoher Qualität stattfinden kann, haben sich ebenfalls viele Menschen einen Kopf gemacht. Grund genug, allen Partnerinnen und Partnern schon vorab unseren herzlichsten Dank für die großartige Unterstützung auszusprechen! 🙏 𝗣𝗿𝗲𝗺𝗶𝘂𝗺𝗽𝗮𝗿𝘁𝗻𝗲𝗿 ▪ IHK Halle-Dessau ▪ GISA GmbH 𝗕𝗲𝘀𝗼𝗻𝗱𝗲𝗿𝗲 𝗨𝗻𝘁𝗲𝗿𝘀𝘁ü𝘁𝘇𝗲𝗿 ▪ Stadtwerke Halle GmbH ▪ Weinberg Campus e.V. ▪ Saalesparkasse ▪ Universitätsmedizin Halle ▪ SONOTEC GmbH ▪ Navigo Proteins GmbH ▪ Investitions- und Marketinggesellschaft Sachsen-Anhalt mbH ▪ Ministerium für Bildung des Landes Sachsen-Anhalt ▪ Stadt Halle (Saale) ▪ Fraunhofer Institute for Microstructure of Materials and Systems IMWS ▪ Roy Coffee Hub #jugendforscht #wissenschaft #nachwuchs Stiftung Jugend forscht e. V.
-
Meet us at the 7th Theranostics World Congress in Santiago de Chile on March 22-24! At Navigo, we apply our expertise in Precision Medicine to custom-design unique, targeted radiotheranostics based on proprietary target binding proteins called Affilins® for the benefits of patients. We are proud to sponsor the 7th Theranostics World Congress and are looking forward to connect to the scientific community hearing about the latest exciting advances in the field. Meet Chris-Carol Bremer (CDO) and Michael Hamm (Head of BD), if you want to collaborate for new projects to help patients in need. #theranostics #imaging #radiopharmaceuticals #TWC2024 #radiomolecular #precisionmedicine #precisiontargeting #oncology #innovation
-
-
Join us in Barcelona at BIO-EUROPE Spring 2024 to see the progress of Navigo Proteins next-generation targeting based on our unique, proprietary Affilin® platform! With a primary focus in Oncology, Affilins® are being developed as radio-conjugates for imaging and therapy (#rlt), protein-drug conjugates (#adc), Affilin®-CARs (#celltherapy) and multi-specifics through our in-house initiatives and partnered programs. Reach out to Chris-Carol Bremer (CDO) and Michael Hamm (Head of BD) to explore how our readily accessible Affilin® ligands can drive targeted therapeutics into clinical development! #bioeuropespring #precisiontargeting for #precisionmedicine #oncology #innovation #nextgenerationconjugates
-
-
🔬 We're thrilled to share that Navigo Proteins GmbH will be attending the Bioprocessing Summit Europe in Barcelona! 🎉 📅 Save the Date: 19-21 March 2024 📍 Location: InterContinental Barcelona Avenida de Rius I Taulet, 1-3 Barcelona, 08004, Spain Meet us to explore the latest advancements in Next-gen Affinity chromatography. Florian Settele – Head of Business Unit Precision Capturing® Joséphine Hammerlindl – Business Development Manager Looking forward to seeing you there! Let's revolutionize bioprocessing together! #bioprocessing #downstream #innovation #biotech #barcelona #affinitychromatography
-
-
Exciting news! Navigo Proteins will be showcasing their groundbreaking innovations at the 3rd Next-Generation Conjugates Summit in Boston from February 26 to 28! Specializing in oncology, their Affilins® platform is revolutionizing targeted therapies. Affilins® offer remarkable potential as radio-conjugates for imaging and therapy, protein-drug conjugates, Affilin®-CARs, bi- and multi-specifics. Their small size, excellent tumor penetration, stability, and ease of manufacturing make them a top choice for next-generation conjugates. Don't miss the presentation by Dr. Chris-Carol Bremer, Chief Development Officer at Navigo Proteins. He'll be sharing insights into our best-in-class targeting platform, showcasing its modularity and effectiveness in advancing cancer treatment. Find the event guide here: https://ter.li/gk21k3 #precisiontargeting for #precisionmedicine #oncology #innovation #nextgenerationconjugates
-
-
Meanwhile in Europe, Navigo is proud to be the Innovation Partner at the 5th Targeted Radiopharmaceutical Summit, Berlin #TRP EU At Navigo we are solving two main challenges for targeted radioligand therapy (#RLT): target-specific delivery and optimal biodistribution, using our toolbox of target specific Affilins® and half-life optimizing HEAD® technology. Don’t miss the presentation by our CSO Ulrich Haupts tomorrow (7th Dec) showcasing the novel Affilin® Radiotheranostics with best-in-class potential and unprecedented modularity for fast innovation. #precisiontargeting for #precisionmedicine #oncology #innovation
-
-
Navigo Proteins is proud to present its Affilin® technology at the 3rd ADC Target Selection Summit in Boston tomorrow! With the #ADC field making strides in developing anti-cancer therapies, this meeting brings together world-class experts to discuss latest developments in target ID, selection and target-specific ADC development that will continue progressing ADCs into and through the clinic. Our CDO Chris-Carol will be presenting Navigo’s novel Affilin® platform of best-in-class target-specific proteins with unparalleled modularity to create multi-specific Affilin®-Drug Conjugates (novel #ADCs). #precisiontargeting for #precisionmedicine #oncology #innovation
-
-
Meet Navigo Proteins next week in Munich at BIO-EUROPE 2023! At Navigo we are developing targeted therapeutics for Precision Medicine based on proprietary novel target binders called Affilins®. With a primary focus in Oncology, Affilins® are being developed as radio-conjugates for imaging and therapy (#rlt ), protein-drug conjugates (#adc ), Affilin®-CARs (#celltherapy ) and multi-specifics through in-house and partnered programs. Reach out to Priyanka and Chris-Carol to explore synergies and foster partnerships with Navigo to create next-generation Affilin®-based targeted therapies! #precisiontargeting for #precisionmedicine #oncology
-